Andrew Baum
Stock Analyst at Citigroup
(1.58)
# 1556
Out of 5,234 analysts
44
Total ratings
52.17%
Success rate
15.31%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Bristol-Myers Squibb | Maintains: Neutral | 55 60 | 56.68 | 5.86% | 8 | Nov 12, 2024 | |
Royalty Pharma | Maintains: Buy | 60 40 | 25.74 | 55.4% | 2 | Oct 25, 2024 | |
Merck & Co | Maintains: Buy | 140 130 | 99.73 | 30.35% | 7 | Oct 25, 2024 | |
AbbVie | Maintains: Strong Buy | 170 215 | 179.81 | 19.57% | 11 | Oct 25, 2024 | |
Eli Lilly and Co | Maintains: Strong Buy | 675 895 | 764.03 | 17.14% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 13.33 | -24.98% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 42 35 | 26.88 | 30.21% | 5 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |